Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

It’s one of the rarest — and most devastating — genetic disorders doctors encounter. Harlequin ichthyosis affects just a handful of newborns each year in the US, but the condition is unmistakable, ...

・Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder. ・The company noted that ichthyosis vulgaris impacts 1.3 ...

Harlequin ichthyosis (HI) is a rare, severe genetic skin disorder caused by ABCA12 mutations, leading to defective lipid transport and loss of skin barrier function. Infants present with thick, ...